- Related Products
MedEx answers any queries you might have regarding Regorafenib-40 purchase, shipping and payment terms.
Feel free to contact support through inquiry form, MedeEx is fully dedicated towards your needs 24/7.
Regorafenib 40 mg is a modern drug that managed to prove its high effectiveness in the treatment of metastatic colorectal cancer and inoperable gastrointestinal stromal tumors, whose standard treatment wasn’t successful.
Regorafenib belongs to the group of target anti-cancer drugs. Regorafenib represents a tyrosine-kinase inhibitor (i.e. it works by identifying and blocking certain receptors, situated on the surface of the cancer cells). Regorafenib inhibits the activity of several receptors, responsible for the growth and replication of cancer cells, as well as the blood supply to the tumor.
Regorafenib 40 mg is prescribed for the treatment of the following diseases:
Colorectal cancer affecting the other parts of the body. The drug is prescribed if the preceding standard therapy had failed.
Locally advanced, inoperable or metastatic gastrointestinal stromal tumors. The treatment is prescribed if the previous therapy with Imanitib mesylate and Sunitib proved ineffective.
Hypersensitivity to any drug component is an absolute contraindication to the use of Regorafenib 40 mg.
Women of childbearing age should be informed that Regorafenib can harm the fetus. Both women and men must use contraceptives during the treatment and at least 8 weeks after discontinuing the therapy with Regorafenib 40 mg.
There are no statistics on the use of Regorafenib 40 mg by the pregnant women. Due to the action principle, there is reason to believe that the treatment can be dangerous for the fetus. Animal studies showed the presence of reproductive toxicity in the drug. Regorafenib can be used only as a last resort, after careful consideration of the benefits for the mother and potential risks for fetus.
It is unknown whether Regorafenib 40 mg or its metabolites gets into the breast milk. However, animal studies have shown that the risk for the breastfed infants can’t be excluded. Therefore, Regorafenib shouldn’t be used during lactation.
Serious side effects that affected less than 1% of patients are: liver damage, severe bleeding, blisters and peeling skin, very high blood pressure that require immediate treatment, heart attack and intestinal perforation.
The most common side effects of Regorafenib 40 mg are: weakness, chronic fatigue, loss of appetite, palmar-plantar erythrodysesthesia, diarrhea, oral sores, weight loss, high risk of infection, increased blood pressure and speech impediment (dysphonia).